研究表明,GLP-1药物降低了肾衰竭的风险,改善了肾和心脏健康。 Study shows GLP-1 drugs reduce kidney failure risk and improve kidney and heart health.

在《柳叶刀糖尿病和内分泌学》上发表的一项新研究表明,GLP-1受体激动剂、糖尿病和肥胖症药物可以大大保护肾脏。 A new study published in The Lancet Diabetes & Endocrinology reveals that GLP-1 receptor agonists, drugs used for diabetes and obesity, can significantly protect kidneys. 对涉及85 373人的11项试验的分析表明,肾衰竭风险减少了16%,与安慰剂相比,肾功能恶化减少了22%。 The analysis of 11 trials involving 85,373 people showed a 16% reduction in kidney failure risk and a 22% reduction in worsening kidney function compared to placebos. 这些药物还降低了肾衰竭、功能恶化和死亡的风险19%。 The drugs also reduced the risk of kidney failure, worsening function, and death by 19%. 此外,GLP-1受体激动剂将心血管疾病的风险降低14%。 Additionally, GLP-1 receptor agonists lowered the risk of cardiovascular issues by 14%.